CATHETER PRECISION INC (VTAK)
US74933X6094 - Common Stock
VTAK gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 188 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of VTAK have multiple concerns. VTAK is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
In the past year VTAK has reported negative net income.
VTAK had a negative operating cash flow in the past year.
In the past 5 years VTAK always reported negative net income.
In the past 5 years VTAK always reported negative operating cash flow.
1.2 Ratios
VTAK has a Return On Assets of -36.14%. This is in the lower half of the industry: VTAK underperforms 60.43% of its industry peers.
VTAK's Return On Equity of -66.29% is in line compared to the rest of the industry. VTAK outperforms 40.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -36.14% | ||
| ROE | -66.29% | ||
| ROIC | N/A |
ROA(3y)-170.3%
ROA(5y)N/A
ROE(3y)-270.08%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
VTAK has a better Gross Margin (92.20%) than 99.47% of its industry peers.
The Profit Margin and Operating Margin are not available for VTAK so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 92.2% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
VTAK does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VTAK has more shares outstanding
VTAK has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -16.46, we must say that VTAK is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -16.46, VTAK is not doing good in the industry: 84.49% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.05 indicates that VTAK is not too dependend on debt financing.
With a decent Debt to Equity ratio value of 0.05, VTAK is doing good in the industry, outperforming 61.50% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -16.46 |
ROIC/WACCN/A
WACC21.05%
2.3 Liquidity
A Current Ratio of 0.12 indicates that VTAK may have some problems paying its short term obligations.
With a Current ratio value of 0.12, VTAK is not doing good in the industry: 97.33% of the companies in the same industry are doing better.
VTAK has a Quick Ratio of 0.12. This is a bad value and indicates that VTAK is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.10, VTAK is not doing good in the industry: 97.33% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.12 | ||
| Quick Ratio | 0.1 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 60.85% over the past year.
The Revenue has grown by 134.41% in the past year. This is a very strong growth!
Measured over the past years, VTAK shows a quite strong growth in Revenue. The Revenue has been growing by 19.50% on average per year.
EPS 1Y (TTM)60.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%51.57%
Revenue 1Y (TTM)134.41%
Revenue growth 3Y19.5%
Revenue growth 5YN/A
Sales Q2Q%-3.12%
3.2 Future
The Earnings Per Share is expected to grow by 24.76% on average over the next years. This is a very strong growth
VTAK is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 107.55% yearly.
EPS Next Y27.89%
EPS Next 2Y29.91%
EPS Next 3Y24.76%
EPS Next 5YN/A
Revenue Next Year65.46%
Revenue Next 2Y114.14%
Revenue Next 3Y107.55%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for VTAK. In the last year negative earnings were reported.
Also next year VTAK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as VTAK's earnings are expected to grow with 24.76% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.91%
EPS Next 3Y24.76%
5. Dividend
5.1 Amount
No dividends for VTAK!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CATHETER PRECISION INC
NYSEARCA:VTAK (11/18/2024, 8:04:00 PM)
After market: 0.4374 +0.01 (+2.1%)0.4284
-0.04 (-8.85%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.20M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -36.14% | ||
| ROE | -66.29% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 92.2% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.12 | ||
| Quick Ratio | 0.1 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)60.85%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y27.89%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)134.41%
Revenue growth 3Y19.5%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y